Develco develops and manufactures innovative drug formulations using modified or prolonged-release technologies, with current therapeutic focuses on severe pain and ADHD. The company handles the full value chain from development and regulatory approval through manufacturing and supply, and outlicenses approved products to international pharmaceutical companies. Demand for Develco’s products and production capacity has grown strongly in recent years, producing a backlog that exceeds twelve months of revenue and driving double-digit revenue growth. With SHS Capital’s earlier involvement since 2020, the company has strengthened its first- and second-level management and augmented its board with industry experts. Develco has expanded production capacity and operational efficiency to meet rising demand. The company plans to use new capital to further scale production, increase investment in product development, and enhance its technological capabilities to capture future growth opportunities.

Total raised

$11M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2024